RDHL News and Press, Redhill Biopharma Ltd. From 11/27/23

2023-11-27 07:49:39 ET DENVER, Colo., Nov 27, 2023 ( www.247marketnews.com )- Redhill Biopharma Ltd (NASDAQ: RDHL) stated, this morning, that the U.S. Food and Drug Administration granted the Company five years’ market exclusivity for Talicia3 under the Generating Antibiotic Ince...

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 PR Newswire The U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infe...

2023-11-14 08:32:02 ET More on RedHill Financial information for RedHill For further details see: RedHill Biopharma receives approval to transfer its listing to the Nasdaq Capital Market

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market PR Newswire TEL AVIV, Israel & RALEIGH, N.C. , Nov. 14, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceut...

2023-10-13 10:53:23 ET More on RedHill Financial information for RedHill For further details see: RedHill Biopharma files to sell 8.86M American Depositary Shares for holders

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study PR Newswire - Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola viru...

2023-09-18 11:20:59 ET DENVER, Colo., Sept 18, 2023 ( www.247marketnews.com )- This morning’s stocks to watch list contains companies from multiple sectors. Stocks (NASDAQ: AVGR,) (NASDAQ:RDHL) and (NASDAQ:SYTA) Redhill Biopharma LTD (NASDAQ:RDHL) announced that the Food ...

RedHill Announces FDA sNDA Approval for Talicia® PR Newswire FDA approves supplemental new drug application (sNDA) for Talicia, changing dosing to a simplified three times daily (TID) regimen, which may support increased patient adherence and treatment outcomes Ta...

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) PR Newswire USPTO issues Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opa...

2023-08-17 08:14:03 ET RedHill press release ( NASDAQ: RDHL ): 1H GAAP EPS of $0.04. Revenue of $5.4M (-82.8% Y/Y). Cash balance of $16.3 million as of June 30, 2023. For further details see: RedHill GAAP EPS of $0.04, revenue of $5.4M